Clearmind Medicine Stock Up 40% on Trial

Clearmind Medicine shares jumped about 40% after announcing its CMND-100 candidate met primary endpoint in Phase I/IIa trial for Alcohol Use Disorder.
The trial showed a high safety and tolerability profile, with no serious adverse events even at the higher dosage in cohort three.
CMND-100 is a non‑hallucinogenic MEAI‑based oral drug, supporting continued development as a potential treatment for moderate to severe Alcohol Use Disorder.